Summit Therapeutics (SMMT)
Summit Therapeutics (SMMT) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.
- SMMT last traded at $10.08 on 2026-11-20, -4.64% for the session.
- Summit Therapeutics: market cap $8.06B.
- Over the past year SMMT returned -39.13%, with a year-to-date return of -42.37%.
Summit Bounces After FDA Setback and New Trial
Summit Therapeutics rose 3.2% today even as the S&P 500 and Nasdaq 100 each fell 1.2%. Traders are weighing the FDA’s rejection of its lung-cancer drug application against a newly launched global trial, after steep recent losses.
Published 2026-11-19 18:00:42 UTC.